The First Longevity Pharma — How Lilly Became the Machine for Immortality

from Tomorrow Unveiled: Your Weekly Tech Briefing

Eli Lilly just entered the longevity race with retatrutide - a triple-receptor drug showing 28% weight loss and cellular aging reversal. We break down how 13 billion dollars in GLP-1 revenue is funding the future of anti-aging medicine, AI drug discovery, and why Big Pharma's institutional validation marks the professionalization of longevity science. This is the moment pharmaceutical scale meets lifespan extension. #GLP1 #Longevity #Retatrutide #EliLilly #AntiAging #Biotech #DrugDiscovery #HealthSpan Watch on YouTube: https://www.youtube.com/watch?v=qaN42HaEWzw

Episode metadata supplied by the publisher feed · Published May 27, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

The First Longevity Pharma — How Lilly Became the Machine for Immortality

0:00 20:04

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Tomorrow Unveiled: Your Weekly Tech Briefing?

This episode is 20 minutes long.

When was this Tomorrow Unveiled: Your Weekly Tech Briefing episode published?

This episode was published on May 27, 2026.

Can I download this Tomorrow Unveiled: Your Weekly Tech Briefing episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!